Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma

Cancer Genetics

Volumn 206, Issue 5, 2013, Pages 145-153

  Sung, Chang Ohk ^a   Choi, Chel Hun ^a   Ko, Young Hyeh ^a   Ju, Hyunjeong ^b   Choi, Yoon La ^a   Kim, Nyunsu ^b   Kang, So Young ^a   Ha, Sang Yun ^a   Choi, Kyusam ^b   Bae, Duk Soo ^a   Lee, Jeong Won ^a   Kim, Tae Joong ^a   Song, Sang Yong ^a   Kim, Byoung Gie ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

ACGH; Clear cell carcinoma; Expression microarray; Ovary; PTK2

Indexed keywords

FOCAL ADHESION KINASE 1;

ADULT; ARTICLE; CHROMOSOME 11P; CHROMOSOME 12P; CHROMOSOME 15P; CHROMOSOME 18P; CHROMOSOME 1Q; CHROMOSOME 22Q; CHROMOSOME 3P; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FEMALE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PTK2 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACGH; CLEAR CELL CARCINOMA; EXPRESSION MICROARRAY; OVARY; PTK2;

ADENOCARCINOMA, CLEAR CELL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; FOCAL ADHESION KINASE 1; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84881244140     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2013.04.002     Document Type: Article

References (34)

1. Anglesio M.S., Carey M.S., Kobel M., et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011, 121:407-415.
2. Kobel M., Kalloger S.E., Huntsman D.G., et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010, 29:203-211.
3. Mackay H.J., Brady M.F., Oza A.M., et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010, 20:945-952.
4. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. JNatl Cancer Inst 2000, 92:699-708.
5. Vasey P.A., Jayson G.C., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. JNatl Cancer Inst 2004, 96:1682-1691.
6. Itamochi H., Kigawa J., Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008, 99:653-658.
7. Sugiyama T., Kamura T., Kigawa J., et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88:2584-2589.
8. Goff B.A., Sainz de la Cuesta R., Muntz H.G., et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996, 60:412-417.
9. Lee Y.Y., Kim T.J., Kim M.J., et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol 2011, 122:541-547.
10. Hirasawa A., Saito-Ohara F., Inoue J., et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003, 9:1995-2004.
11. Suehiro Y., Sakamoto M., Umayahara K., et al. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 2000, 59:50-56.
12. Tan D.S., Lambros M.B., Rayter S., et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009, 15:2269-2280.
13. Tan D.S., Iravani M., McCluggage W.G., et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011, 17:1521-1534.
14. Anglesio M.S., Arnold J.M., George J., et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008, 6:1678-1690.
15. Kobel M., Kalloger S.E., Boyd N., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232.
16. Tothill R.W., Tinker A.V., George J., et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008, 14:5198-5208.
17. Anglesio M.S., George J., Kulbe H., et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
18. Zorn K.K., Bonome T., Gangi L., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11:6422-6430.
19. Tan D.S., Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. JClin Pathol 2007, 60:355-360.
20. Mermel C.H., Schumacher S.E., Hill B., et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011, 12:R41.
21. Beroukhim R., Getz G., Nghiemphu L., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007, 104:20007-20012.
22. Cox B.D., Natarajan M., Stettner M.R., et al. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. JCell Biochem 2006, 99:35-52.
23. Schaller M.D. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. JCell Sci 2010, 123:1007-1013.
24. McLean G.W., Komiyama N.H., Serrels B., et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev 2004, 18:2998-3003.
25. Judson P.L., He X., Cance W.G., et al. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999, 86:1551-1556.
26. Sood A.K., Coffin J.E., Schneider G.B., et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004, 165:1087-1095.
27. Mabuchi S., Kawase C., Altomare D.A., et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 2010, 9:2411-2422.
28. Cabrita M.A., Jones L.M., Quizi J.L., et al. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol 2011, 5:517-526.
29. Lechertier T., Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. JPathol 2012, 226:404-412.
30. Tavora B., Batista S., Reynolds L.E., et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2010, 2:516-528.
31. Wiegand K.C., Shah S.P., Al-Agha O.M., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. NEngl J Med 2010, 363:1532-1543.
32. Jones S., Wang T.L., IeM Shih, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-331.
33. Mamo A., Cavallone L., Tuzmen S., et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012, 31:2090-2100.
34. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.